Benzinga Pro
Marketfy
Financial Data & APIs
Events
Premarket Prep
Membership is Free
What are you waiting for? Sign up now!
Name:
Username available!
Username taken!
Email:
Email available!
Email taken!
Password:
Leave blank:
OR
Free Account Login
Click here to access your premium account
Username or email:
Password:
OR
Forgot password?
Contribute
Login
Join
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap
Cryptocurrency
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Tech
Start-Ups
Fintech
Investing
Best Online Brokers
Personal Finance
Compare Brokers
Interactive Brokers Review
TD Ameritrade Review
Ally Invest Review
Etrade Review
Personal Capital Review
Tradestation Review
Forex.com Review
Binary Options Review
Suretrader Review
Yewno|Edge Review
Premium
Market Overview
Tickers
Articles
Keywords
Search by keyword...
googlecse
WANT TO CATCH
PTGX
NEWS
BEFORE
IT CHANGES THE STOCK PRICE?
More From
Summary
Ideas
Twitter ($)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries
Protagonist Therapeutics, Inc.
PTGX
:NASDAQ
Add to Watchlist +
{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists
Sector:
Healthcare
Industry:
Biotechnology
7.350
-0.07 (-0.94%)
Data as of Feb 17, 2019
Prev. Close
7.42
Price Open
7.35
Volume
51,213
Day's Range
7.16 - 7.49
52 Wk Range
5.4927 - 23.97
50 Day Moving Avg.
7.28
PE Ratio
0
Shares Outstanding
25.19M
Market Cap
185.12M
Trade PTGX stock with
recommended broker Ally Invest
. Commissions as low as $3.95.
1d
5d
1m
3m
1y
5y
YTD
Analyst Rating
View All Ratings
Date
Research Firm
Action
Current
Target
12/06/18
Nomura
Initiates Coverage On
Buy
13.0
6/06/18
Barclays
Downgrades
Overweight
Equal-Weight
0.0
3/27/18
BMO Capital
Maintains
Outperform
Outperform
13.0
Headlines
Press Releases
48 Biggest Movers From Yesterday
Lisa Levin
Fri, 18 Jan 2019 05:06:56 -0500
Protagonist Therapeutics Initiates Phase 2 Trial Of Novel Hepcidin Mimetic PTG-300 For Beta Thalassemia
Benzinga Newsdesk
Wed, 09 Jan 2019 07:02:16 -0500
UPDATE: Protagonist Says Dinseh Patel To Serve As Interim Principal Financial Officer, Niall Murphy To Act As Interim Principal Accounting Officer
Benzinga Newsdesk
Mon, 31 Dec 2018 16:28:08 -0500
Protagonist Therapeutics 8-K Shows CFO Thomas O'Neil Voluntarily Resigned
Benzinga Newsdesk
Mon, 31 Dec 2018 16:27:17 -0500
Protagonist Therapeutics Reports Initiation Of Phase 1 Trial Of PN-10943
Benzinga Newsdesk
Thu, 13 Dec 2018 07:08:34 -0500
Nomura Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces $13 Price Target
Vick Meyer
Thu, 06 Dec 2018 09:06:13 -0500
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018
Benzinga Newsdesk
Thu, 29 Nov 2018 10:59:22 -0500
The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved
Shanthi Rexaline
Thu, 29 Nov 2018 08:09:42 -0500
40 Biggest Movers From Yesterday
Lisa Levin
Thu, 29 Nov 2018 05:33:31 -0500
36 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
Wed, 28 Nov 2018 12:19:53 -0500
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Investor Expectations to Drive Momentum within Continental Resources, Protagonist Therapeutics, Mobile Mini, J & J Snack Foods, Griffon, and Nordson — Discovering Underlying Factors of Influence
Globe Newswire
Feb 05, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
PRNewswire
Jan 16, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
PRNewswire
Jan 09, 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
PRNewswire
Jan 07, 2019
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
PRNewswire
Dec 13, 2018
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
PRNewswire
Dec 05, 2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
PRNewswire
Nov 27, 2018
New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Consolidated Revenues, Company Growth, and Expectations for 2018
Globe Newswire
Nov 09, 2018
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14
PRNewswire
Nov 07, 2018
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
PRNewswire
Nov 06, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Partner Headlines
Dosing underway in mid-stage study of Protagonist's PTG-300 in beta thalassemia
Seeking Alpha
Jan 09, 2019
Marketplace Authors' Top Picks For 2019
Seeking Alpha
Jan 06, 2019
Protagonist finance chief to bid adieu
Seeking Alpha
Dec 31, 2018
Keeping Focused Amidst The Biotech Bear
Seeking Alpha
Dec 28, 2018
Protagonist launches early-stage study of integrin antagonist for IBD
Seeking Alpha
Dec 13, 2018
Microcaps dominate midday movers
Seeking Alpha
Nov 28, 2018
Alliqua BioMedical and Aerpio Pharmaceuticals among Healthcare gainers; Arsanis and Protagonist Therapeutics among the losers
Seeking Alpha
Nov 28, 2018
Protagonist down 15% after bailing on IBD candidate PTG-100
Seeking Alpha
Nov 28, 2018
Investors returning to tiny biotechs
Seeking Alpha
Nov 16, 2018
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
Zacks
Nov 06, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Earnings
View Earnings
Q3 2018
EST
Actual
Surprise
EPS:
-0.37
-0.38
-0.01
Rev:
6.43M
6.12M
-313.00K
Q4 2018
EST
Actual
Surprise
EPS:
Expected
2019-03-06
Rev:
WILL
PTGX
SPIKE ON TOMORROW'S NEWS?
Stocks like
PTGX
are creating awesome opportunities based on catalysts in the news. Is
PTGX
the next one to get some major price action?
Create a Benzinga Pro account today to find out.
Company Profile
Read More
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
Brokerage Center
Compare All Online Brokerages
Benzinga - Feed Your Mind
try pro
News
Markets
Ratings
Ideas
Tech
Small-Cap
Personal Finance
Premium Products
